Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.

Journal of gynecologic oncology - 1 Mar 2024

Wang Hao, Li Yinuo, Wang Yanan, Shang Xiumin, Yan Zhongxin, Li Shengli, Bao Wei

Abstract excerpt

OBJECTIVE: We previously elucidated that long non-coding RNA Promoter of CDKN1A Antisense DNA damage Activated RNA (PANDAR) as a p53-dependent oncogene to promote cisplatin resistance in ovarian cancer (OC). Intriguingly, high level of p53-independent PANDAR was found in cisplatin-resistant patients with p53 mutation. Here, our study probed the new roles and the underlying mechanisms of PANDAR in p53-mutant OC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cisplatin
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exosomes

Share to In Situ Hybridization, Fluorescence

Share to Mitochondrial Proteins

Share to Ovarian Neoplasms

Share to Sirtuins

Source

Open in PubMed Open full text

Identifiers

PMID: 37921598
DOI: 10.3802/jgo.2024.35.e13
PMCID: PMC10948987

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.PMID 37921598Read ↗

Long Noncoding RNAs as Biotargets in Cisplatin-Based Drug ResistanceSemantic proximity Read ↗

GSR Mediates Cisplatin Resistance in Oral Cancer by Protecting MitochondriaSemantic proximity Read ↗

Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.Semantic proximity Read ↗

Exosomes as mediators of platinum resistance in ovarian cancer.Semantic proximity Read ↗

Evaluation of Long Non-coding RNA (LncRNA) in the Pathogenesis of Chemotherapy Resistance in Cervical Cancer: Diagnostic and Prognostic ApproachSemantic proximity Read ↗

The role of microRNA in cisplatin resistance or sensitivitySemantic proximity Read ↗

CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.Semantic proximity Read ↗

MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell linesSemantic proximity Read ↗

N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulationSemantic proximity Read ↗

Exosomal circZFR promotes colorectal cancer progression via stabilizing BCLAF1 and regulating the miR-3127-5p/RTKN2 axisSemantic proximity Read ↗

An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinomaSemantic proximity Read ↗

Exosomal circZFR promotes colorectal cancer progression via interacting with BCLAF1 and regulating the miR-3127-5p/RTKN2 axisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.